Since thiazolidinedione-based precision medicine may be beneficial for patients with PPARγ variant-induced diabetes (PPARG-DM), it is necessary to determine the prevalence of PPARG-DM and develop clinical strategies for screening this condition. Here, PPARG is linked to diabetes mellitus.